Minerva COO holds 20,872 shares plus stock options

Q: What does the Form 3 for NERV disclose about Joseph H. Reilly?

The Form 3 shows that Minerva Neurosciences COO Joseph H. Reilly directly holds 20,872 common shares and multiple employee stock options on common stock with exercise prices from $2.12 to $28.00 per share, expiring between 2030 and 2036.

Q: How many NERV common shares does Joseph H. Reilly directly own?

Joseph H. Reilly directly owns 20,872 shares of Minerva Neurosciences, Inc. common stock as reported in this Form 3. This reflects his reported direct ownership position in the company’s equity, separate from his employee stock options.

Q: How many NERV shares underlie Joseph H. Reilly’s largest option positions?

Two of the largest reported option positions cover 750,000 underlying shares at an exercise price of $3.98 per share, expiring December 21, 2035, and 680,000 underlying shares at an exercise price of $4.68 per share, expiring June 2, 2036.

Q: Which of Joseph H. Reilly’s NERV options are already fully vested?

Options with exercise prices of $28.00 and $6.33 per share are described as fully vested. Other option grants vest 25% on specified dates starting between 2023 and 2027, then in equal quarterly installments over three years.

Q: What are the vesting terms for Joseph H. Reilly’s more recent NERV option grants?

One grant for 750,000 underlying shares at $3.98 per share vests 25% on December 22, 2026 then quarterly over three years. Another for 680,000 underlying shares at $4.68 per share vests 25% on June 3, 2027 then quarterly over three years.

Minerva Neurosciences, Inc. (ticker NERV) reported initial insider holdings for Chief Operating Officer Joseph H. Reilly.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. (ticker NERV) reported initial insider holdings for Chief Operating Officer Joseph H. Reilly. He directly owns 20,872 shares of common stock. He also holds several employee stock options on common stock at exercise prices between $2.12 and $28.00 per share with expirations from 2030 through 2036.

Two option grants with exercise prices of $28.00 and $6.33 are noted as fully vested. Other grants follow time-based vesting schedules that begin between 2023 and 2027, typically vesting 25% on a specified date and then in equal quarterly installments over three years.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Reilly Joseph H.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) ^F1	--	--	--
holding	Employee Stock Option (right to buy) ^F1	--	--	--
holding	Employee Stock Option (right to buy) ^F2	--	--	--
holding	Employee Stock Option (right to buy) ^F3	--	--	--
holding	Employee Stock Option (right to buy) ^F4	--	--	--
holding	Employee Stock Option (right to buy) ^F5	--	--	--
holding	Employee Stock Option (right to buy) ^F6	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 1,593,725 contracts (Direct); Common Stock — 20,872 shares (Direct)

Footnotes (6)

F1. Fully vested.
F2. The option vested 25% on December 13, 2023 and then vests or vested in equal quarterly installments over 3 years thereafter.
F3. The option vested 25% on October 4, 2024 and then vests or vested in equal quarterly installments over 3 years thereafter.
F4. The option vested 25% on December 5, 2025 and then vests or vested in equal quarterly installments over 3 years thereafter.
F5. The option vests 25% on December 22, 2026 and then in equal quarterly installments over 3 years thereafter.
F6. The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.

Key Figures

Direct common shares held: 20,872 shares Option exercise price: $28.00 per share Underlying shares at $28.00: 10,625 shares +5 more

8 metrics

Direct common shares held 20,872 shares Direct ownership of Minerva Neurosciences, Inc. common stock by Joseph H. Reilly

Option exercise price $28.00 per share Employee stock option on 10,625 underlying common shares expiring October 12, 2030

Underlying shares at $28.00 10,625 shares Underlying common shares for option with $28.00 exercise price

Largest option underlying shares 750,000 shares Underlying common shares for option with $3.98 exercise price expiring December 21, 2035

Second-largest option underlying shares 680,000 shares Underlying common shares for option with $4.68 exercise price expiring June 2, 2036

Option exercise price $2.12 per share Employee stock option on 47,500 underlying common shares expiring December 4, 2034

First vesting date for 750,000-share option December 22, 2026 25% vests on this date, then in equal quarterly installments over 3 years

First vesting date for 680,000-share option June 3, 2027 25% vests on this date, then in equal quarterly installments over 3 years

Key Terms

Employee Stock Option (right to buy), underlying security, vests or vested in equal quarterly installments, fully vested

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock"

vests or vested in equal quarterly installments financial

"then vests or vested in equal quarterly installments over 3 years thereafter"

fully vested financial

"Footnote F1 states: Fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for NERV disclose about Joseph H. Reilly?

The Form 3 shows that Minerva Neurosciences COO Joseph H. Reilly directly holds 20,872 common shares and multiple employee stock options on common stock with exercise prices from $2.12 to $28.00 per share, expiring between 2030 and 2036.

How many NERV common shares does Joseph H. Reilly directly own?

Joseph H. Reilly directly owns 20,872 shares of Minerva Neurosciences, Inc. common stock as reported in this Form 3. This reflects his reported direct ownership position in the company’s equity, separate from his employee stock options.

What stock options on NERV does Joseph H. Reilly hold and at what exercise prices?

He holds several employee stock options on NERV common stock, including options with exercise prices of $28.00, $6.33, $3.11, $6.41, $2.12, $3.98, and $4.68 per share, each with different expiration dates from 2030 to 2036.

How many NERV shares underlie Joseph H. Reilly’s largest option positions?

Two of the largest reported option positions cover 750,000 underlying shares at an exercise price of $3.98 per share, expiring December 21, 2035, and 680,000 underlying shares at an exercise price of $4.68 per share, expiring June 2, 2036.

Which of Joseph H. Reilly’s NERV options are already fully vested?

Options with exercise prices of $28.00 and $6.33 per share are described as fully vested. Other option grants vest 25% on specified dates starting between 2023 and 2027, then in equal quarterly installments over three years.

What are the vesting terms for Joseph H. Reilly’s more recent NERV option grants?

One grant for 750,000 underlying shares at $3.98 per share vests 25% on December 22, 2026 then quarterly over three years. Another for 680,000 underlying shares at $4.68 per share vests 25% on June 3, 2027 then quarterly over three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/20/2026 - 04:40 PM Accepted by SEC EDGAR 08/20/2026 - 04:40 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reilly Joseph H.

(Last)

(First)

(Middle)

C/O MINERVA NEUROSCIENCES, INC.

1500 DISTRICT AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20,872	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	10/12/2030	Common Stock	10,625	$28	D
Employee Stock Option (right to buy)	⁽¹⁾	02/15/2032	Common Stock	22,500	$6.33	D
Employee Stock Option (right to buy)	⁽²⁾	12/12/2032	Common Stock	27,000	$3.11	D
Employee Stock Option (right to buy)	⁽³⁾	10/03/2033	Common Stock	56,100	$6.41	D
Employee Stock Option (right to buy)	⁽⁴⁾	12/04/2034	Common Stock	47,500	$2.12	D
Employee Stock Option (right to buy)	⁽⁵⁾	12/21/2035	Common Stock	750,000	$3.98	D
Employee Stock Option (right to buy)	⁽⁶⁾	06/02/2036	Common Stock	680,000	$4.68	D

Explanation of Responses:

1. Fully vested.

2. The option vested 25% on December 13, 2023 and then vests or vested in equal quarterly installments over 3 years thereafter.

3. The option vested 25% on October 4, 2024 and then vests or vested in equal quarterly installments over 3 years thereafter.

4. The option vested 25% on December 5, 2025 and then vests or vested in equal quarterly installments over 3 years thereafter.

5. The option vests 25% on December 22, 2026 and then in equal quarterly installments over 3 years thereafter.

6. The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.

	/s/ Frederick Ahlholm, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR